Nuclear Medicine Center in Astana commences production of four radiopharmaceuticals

Nuclear Medicine Center in Astana commences production of four radiopharmaceuticals

Kazakhstan has started producing a new radiopharmaceutical, 18F-DOPA, which is essential for the timely diagnosis of a complex condition – neuroendocrine oncological pathology. The medication is being produced in the country for the first time by the Nuclear Medicine Center at the Medical Centre Hospital of the President’s Affairs Administration of Kazakhstan. The production of four radiopharmaceuticals has already been launched, including fluorodeoxyglucose, sodium fluoride, methionine carbon, and dehydroxyphenylalanine. Currently, six medications are used for tomography and CT studies, enabling to carry out more than 20 types of diagnostics.